Ipamorelin – 5MG
About Ipamorelin – 5MG
Ipamorelin is a synthetic pentapeptide and a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), the receptor for the endogenous peptide ghrelin. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporates non-natural residues (aminoisobutyric acid and D-configured amino acids) that confer stability and receptor selectivity. In laboratory models it is studied as a growth-hormone secretagogue that stimulates GH release through a pathway distinct from, and complementary to, GHRH-receptor signaling.
A defining feature of Ipamorelin in the research literature is its selectivity: unlike earlier growth hormone releasing peptides, it stimulates GH release with minimal effect on the release of ACTH, cortisol or prolactin in model systems. This clean pharmacological profile has made it a widely used tool compound for isolating ghrelin-receptor-mediated GH secretion. Supplied as a lyophilized powder for research use only.
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
Handling and Storage Tips:
Keep peptides cold and away from light once received.
For short-term use (days to weeks), refrigeration at 4°C (39°F) is acceptable.
Lyophilized peptides are typically stable at room temperature for several weeks, making it suitable for moderate-term storage.
For long-term storage (months to years), it’s best to freeze peptides at -80°C (-112°F). Freezing optimally preserves peptide stability for extended periods.
FDA Disclosure & Intended Use:
FDA Disclosure: The statements on this website and the products sold herein have not been evaluated by the U.S. Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure, or prevent any disease. Products sold are for Research Use Only and are not for human or animal use.
Intended Purpose: Products sold on this site are intended solely for basic laboratory research, pharmaceutical research, or the development of new tests. They are not intended for diagnostic, therapeutic, or clinical use.
Specifications
- MaterialIpamorelin – 5MG
- Research AreaGrowth Hormone Research
- Presentation—
- CAS Number170851-70-4
- Molecular FormulaC38H49N9O5
- Molecular Weight711.9 g/mol
- TypeSynthetic pentapeptide (growth hormone secretagogue)
- Receptor / TargetGrowth hormone secretagogue receptor (GHS-R1a / ghrelin receptor)
- PubChem CID9831659 →
Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Purity (HPLC)≥99%
- Identity (MS)Confirmed to specification
- TestingAccredited (ISO 17025) third-party laboratory
- DocumentationPer-batch COA →
Preclinical characterization identified Ipamorelin as one of the first GHS-R agonists to combine potent GH-releasing activity with a high degree of selectivity, releasing GH without the concomitant increases in ACTH and cortisol observed with earlier growth hormone releasing peptides. This selectivity has been reproduced across in vitro pituitary and in vivo rodent model systems.
Later research explored Ipamorelin in models of gastrointestinal motility and postoperative ileus; a clinical development program was ultimately discontinued for lack of efficacy in that indication, but the compound remains a standard selective GHS-R tool in secretagogue research.
Ipamorelin was developed in the late 1990s at Novo Nordisk as part of a program to design selective growth hormone secretagogues, and was first described by Raun and colleagues in 1998. It was later investigated clinically by Helsinn Therapeutics for postoperative ileus. Though not approved as a therapeutic, it has become one of the most widely referenced selective ghrelin-receptor agonists in GH-axis research.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416.
- Beck DE, et al. Evaluation of ipamorelin in the management of postoperative ileus after partial bowel resection. J Gastrointest Surg. 2014;18(9):1659-1666.
View compound profile on NIH PubChem →
Cited literature refers to laboratory and preclinical research. This material is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
Are these research materials third-party tested?
Yes — every batch is analysed by an accredited (ISO 17025) independent laboratory using HPLC and mass spectrometry, with a per-batch Certificate of Analysis.
What purity are the materials?
Materials are verified to 99%+ HPLC purity. Any batch that does not meet the threshold is not released.
Do you provide a Certificate of Analysis (COA)?
Yes. Per-batch COA documentation is provided and is traceable by lot number.
Where do you ship from?
Materials are shipped from the USA in discreet, protective packaging.
Are these products for human use?
No. All materials are sold strictly for laboratory research use only — not for human or animal consumption, diagnosis, treatment, or prevention of any disease.
More Growth Hormone Research materials
✓ ≥99% View COA ›
IGF-1 LR3 1MG Research Vial - Long-Acting IGF-1 Analogue | Third-Party Tested
RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USE · 21+
